FDA names permanent CDER director, boosts safety office

The FDA selected Gerald Dal Pan as director of the Office of Drug Safety in the Center for Drug Evaluation and Research (CDER). 
Dal Pan will report directly to the head of CDER, elevating the stature of the safety office to a level on par with the Office of New Drugs, which approves new medicines for sale, an FDA spokeswoman told MM&M.
Dal Pan joined the FDA in 2000. He most recently served as director, division of surveillance, research, and communication support, Office of Drug Safety in CDER, a position he has held since 2003. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions